Oncotelic Therapeutics ( (OTLC) ) has released a notification of late filing.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Oncotelic Therapeutics, Inc. has filed a Form 12b-25, indicating a delay in submitting its Form 10-K (Yearly Report) for the financial period ending December 31, 2024. The primary reason for the delay is the company’s inability to compile the necessary financial information without incurring unreasonable effort or expense. Oncotelic Therapeutics anticipates filing the report within the extension period allowed by the SEC, which is the fifteenth calendar day following the prescribed due date. The company does not expect any significant changes in its financial results compared to the previous fiscal year. The notification was signed by Amit Shah, the Chief Financial Officer, who assured ongoing compliance efforts.
More about Oncotelic Therapeutics
YTD Price Performance: 100%
Average Trading Volume: 147,629
Technical Sentiment Signal: Sell
Current Market Cap: $28.02M
Learn more about OTLC stock on TipRanks’ Stock Analysis page.